The next application submission deadline for The PREVENT Cancer Preclinical Drug Development Program is September 8, 2015.<\/p>\n
The PREVENT Program was created in 2011 to provide investigators with novel ideas for interventions aimed at cancer prevention access to the National Cancer Institute\u2019s (NCI) contract resources. Intervention strategies of high interest to PREVENT include chemoprevention and immunoprevention. Current areas of focus are:<\/p>\n
?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Antiinflammatory approaches
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Immunoprevention
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Novel mechanisms
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Drug repurposing
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reducing toxicity (dosing and combinations)<\/p>\n
The PREVENT Program application will not directly lead to a grant or contract award; rather NCI may allocate various contract resources and expertise towards implementation and development of approved, scientifically meritorious projects.<\/p>\n
Examples of resources available from PREVENT are:
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In vitro and in vivo preclinical pharmacology and efficacy studies
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Preclinical Investigational New Drug (IND)-directed GLP toxicology studies
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Identification and evaluation of intermediate biomarkers
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Scale-up cGMP and non-cGMP production of an investigational agent
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PK and PK-PD modeling to optimize dosing regimen
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Formulation optimization for enhanced bioavailability and clinical usefulness
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Analytical method development for investigational agents in bulk form and in biological fluids and tissues
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Stability testing for bulk and formulated material
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Regulatory support
\n?\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Other resources to support drug development<\/p>\n
Applications are accepted twice per year (March and September) and subjected to peer-review.
\nResearchers in academia, government, and industry, nationally and internationally, are encouraged to apply.<\/p>\n
PREVENT applications can be found at: http:\/\/prevention.cancer.gov\/major-programs\/prevent-cancer-preclinical\/instructions-applying<\/a><\/p>\n For more information about the PREVENT Program, go to: http:\/\/prevention.cancer.gov\/major-programs\/prevent-cancer-preclinical<\/a><\/p>\n Questions about PREVENT can be sent to:<\/p>\n PREVENT Cancer Program The next application submission deadline for The PREVENT Cancer Preclinical Drug Development Program is September 8, 2015. The PREVENT Program was created in 2011 to provide investigators with novel ideas for interventions aimed at cancer prevention access to the National Cancer Institute\u2019s (NCI) contract resources. Intervention strategies of high interest to PREVENT include chemoprevention and… Continue reading
\nDivision of Cancer Prevention
\nNational Cancer Institute
\nNational Institutes of Health
\n9609 Medical Center Dr., MSC 9787
\nRockville, MD 20850
\nemail: NCIPREVENT@mail.nih.gov<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"